DALLAS, April 28, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/VVUS
VIVUS Inc. (VVUS) is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company's product pipeline includes three late-stage clinical products. One of these investigational products, Qnexa, is in phase III clinical trials for obesity and in phase II clinical trials for diabetes. The Company's late-stage investigational product pipeline includes Qnexa for obesity, for which two phase III studies are in process and one phase III study has been completed; Qnexa, for treating diabetes, for which a one-year phase II study has been completed; Avanafil, which is being developed for the treatment of erectile dysfunction, for which phase III studies are in process; and Luramist (Testosterone MDTS), to treat hypoactive sexual desire disorder in women, for which a phase II study has been completed.
Message Board Search for VVUS: http://www.boardcentral.com/boards/VVUS
In the report, the analyst notes:
"Product revenues from the sale of MUSE in the fourth quarter of 2009 were $8.5 million as compared to $7.8 million in the fourth quarter of 2008, primarily due to a modest increase in shipments and an increase in domestic prices in 2009. Total revenue for the fourth quarter of 2009 was $8.6 million, as compared to $28.8 million for the fourth quarter of 2008. The decrease in total revenue in the fourth quarter of 2009 compared to the fourth quarter last year was primarily due to the inclusion of deferred license revenue from the sale of Evamist in the fourth quarter of 2008.
"VVUS currently has five late stage clinical development programs in progress that target obesity, diabetes, sleep apnea and sexual health. Current research suggests that there is significant unmet need among patients living with these conditions."
To read the entire report visit: www.microstockprofit.com/ads/VVUS
See what investors are saying about VVUS at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.